Dapagliflozin compared with other oral anti‐diabetes treatments when added to metformin monotherapy: a systematic review and network meta‐analysis
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aims: Indirect evidence from randomized controlled trials (RCTs) was used to estimate the effect of dapagliflozin, a new agent with a novel mechanism of action (SGLT‐2 inhibition), relative to other anti‐diabetes therapies after 1 year of treatment. Methods: A systematic literature review and Bayesian network meta‐analysis (NMA) of RCTs involving anti‐diabetes treatments added to metformin were conducted. RCTs enrolling subjects with type 2 diabetes inadequately controlled on metformin monotherapy were included. Comparators included dipeptidyl peptidase‐4 (DPP‐4) inhibitors, thiazolidinediones (TZDs), sulphonylureas, glucagon‐like peptide‐1 (GLP‐1) analogues and dapagliflozin. Outcomes of interest were mean change from baseline HbA1c, weight and systolic blood pressure, and incidence of hypoglycaemia. Results: From 4270 abstracts, six RCTs were included in the primary analysis; no RCTs involving GLP‐1 analogues met primary inclusion criteria. All RCTs were actively controlled with sulphonylureas. The mean change in HbA1c from baseline was similar across comparators. The treatment effect (95% credible interval) of dapagliflozin on HbA1c was −0.08% (−0.25, 0.10) relative to DPP‐4 inhibitors, −0.02% (−0.24, 0.21) relative to TZDs and 0.00% (−0.16, 0.16) relative to sulphonylureas. Non‐sulphonylureas showed significantly lower risk of hypoglycaemia relative to sulphonylureas. Dapagliflozin had a significant effect on weight change: the relative difference was −2.74 kg (−5.35, −0.10) compared with DPP‐4 inhibitors, and −4.67 kg (−7.03, −2.35) compared with sulphonylureas. Systolic blood pressure was not meta‐analysed due to infrequent reporting. Conclusion: Compared with DPP‐4 inhibitors, TZDs and sulphonylureas, dapagliflozin offers similar HbA1c control after 1 year, with similar or reduced risk of hypoglycaemia and the additional benefit of weight loss, when added to metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · cited 3×
“The primary goal of T2DM management is to reduce the risk of micro- and macrovascular complications by achieving and maintaining glycaemic control, while minimizing side effects and accommodating patient preferences [1,2].”
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · cited 1×
“Dapagliflozin, DPP4 inhibitors and TZDs were associated with a reduced risk of hypoglycaemia compared with the currently recommended add-on treatment of sulphonylureas, while offering similar glycaemic control [38,39].”
BackgroundChecking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 1×
“A critical assumption underlying NMA is that of exchangeability: that trials in the network are sufficiently similar in design, outcomes definition and enrolled patient population that the true mean relative effect size that would be estimated using the design of a trial comparing A versus B would be the same, allowin…”
MethodWing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Evaluation of networks of randomized trials
Salanti, G., Higgins, J. P., Ades, A., & Ioannidis, J. P. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207080643 · Cited by 1,078
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Phung, O. J. (2010) · JAMA · doi:10.1001/jama.2010.405 · Cited by 520
Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward
Turchin, A., Matheny, M. E., Shubina, M., Scanlon, J. V., Greenwood, B., & Pendergrass, M. L. (2009) · Diabetes Care · doi:10.2337/dc08-2127 · Cited by 453 · cited 1×
“Hypoglycaemic episodes, primarily those that are severe, lead to ambulance calls and hospital admissions [50], road accidents [51], and may be associated with an increased risk of death [52,53].”
BackgroundThe impact of non-severe hypoglycemic events on work productivity and diabetes management
Brod, M., Christensen, T., Thomsen, T. L., & Bushnell, D. M. (2011) · Value in Health · doi:10.1016/j.jval.2011.02.001 · Cited by 284 · cited 1×
“Even nonsevere hypoglycaemic episodes are associated with considerable lost productivity (approximately 10 h per episode), and outof-pocket expenses [54].”
BackgroundGlucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
List, J. F., & Whaley, J. M. (2011) · Kidney International · doi:10.1038/ki.2010.512 · Cited by 184 · cited 1×
“Dapagliflozin is the first sodium-glucose co-transporter (SGLT) inhibitor, a new class of anti-diabetes treatments, with a novel and insulin-independent mechanism of action [10].”
BackgroundCharbonnel, B., Schernthaner, G., Brunetti, P., Matthews, D. R., Urquhart, R., Tan, M. H., & Hanefeld, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1751-1 · Cited by 170 · cited 1×
“For example, following the reduction in glycated haemoglobin (HbA1c) experienced in the first 10–24 weeks, patients treated with sulphonylureas tend to rebound over the subsequent 6 to 18 months [17,18].”
BackgroundExenatide Versus Glibenclamide in Patients with Diabetes
Derosa, G., Maffioli, P., Salvadeo, S. A. T., Ferrari, I., Ragonesi, P. D., Querci, F., Franzetti, I. G., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., et al. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0141 · Cited by 125 · cited 2×
“The two remaining studies involved GLP-1 analogues [25,26], and were included only in a sensitivity analysis, owing to their trial design that included an intensive approach to diet and exercise.”
BackgroundMethod
Cited by
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
“Given their demonstrated efficacy and clinical experience to date, they are reasonable options as second-line or third-line agents [40–42] (Fig.”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 694
Scheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Zaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D., Khunti, K., & Davies, M. J. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12670 · Cited by 489
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16162965 · Cited by 300
“02% relative to the one induced by TZDs, while similar HbA1c reduction was observed when compared with treatment with SUs [30].”
BackgroundMethodResultInfluential
Metadata
- Authors
- Goring, S., Hawkins, N., Wygant, G., Roudaut, M., Townsend, R., Wood, I., & Barnett, A. H.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-12-16
- Volume
- 16
- Issue
- 5
- Pages
- 433-442
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2153688222
- Cited by
- 96
- References
- 12
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.